Formosa & DÁVI Farmacêutica Announce Clobetasol Licensing Deal
31 Oct 2024 //
PR NEWSWIRE
Formosa Ships APP13007 To US For Commercialization
09 Sep 2024 //
PR NEWSWIRE
Formosa Pharma And Eyenovia Initiate Co-Development Of Clobetasol Suspension
08 Aug 2024 //
PR NEWSWIRE
Formosa Pharma Licenses Clobetasol Eye Drug To Apotex
05 Aug 2024 //
PR NEWSWIRE
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
10 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Formosa, Tabuk Deal For Ocular Surgery Ophthalmic Suspension
09 May 2024 //
PR NEWSWIRE
US FDA approves Eyenovia`s eye drug, Formosa Pharma says
05 Mar 2024 //
REUTERS
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália
26 Jan 2024 //
PR NEWSWIRE
Formosa sells Brazilian rights to near-approval eye drug
26 Jan 2024 //
FIERCE BIOTECH
Formosa Pharma inks $86 M worth ophthalmology deal with American firm Eyenovia
21 Aug 2023 //
BIOSPECTRUM ASIA
Formosa Announces Agreement with Eyenovia for the Commercialization of APP13007
16 Aug 2023 //
PR NEWSWIRE
Formosa, AimMax submit NDA to FDA for new pain therapy
08 May 2023 //
PHARMACEUTICAL-TECHNOLOGY
Formosa & AimMax Announce the NDA Submission to the US FDA for APP13007
04 May 2023 //
PR NEWSWIRE
Formosa Pharma Announces Development Collaboration Agreement with Eyenovia
15 Feb 2023 //
PR NEWSWIRE
Eyenovia and Formosa partner for new ophthalmic therapeutics
15 Feb 2023 //
PHARMACEUTICAL TECHNOLOGY
Taiwan strengthens treatment for inflammation & pain post cataract surgery
13 May 2022 //
BIOSPECTRUMASIA
Formosa and AimMax Announce Successful Top-Line Results from CPN-301
12 May 2022 //
PRNEWSWIRE